Application for regulatory approval of apixaban in Europe to be submitted

NewsGuard 100/100 Score
Editorial Checklist Reviewed
Dec 4 2009

Bristol-Myers Squibb Company (NYSE: BMY) and Pfizer (NYSE: PFE) today announced that the companies are planning to submit an application for regulatory approval of apixaban in Europe for the prevention of venous thromboembolism (VTE) after orthopedic surgery in the first half of 2010. The application will be supported by ADVANCE-2 and ADVANCE-3, two clinical trials that evaluated apixaban versus the European dosing regimen of enoxaparin for prevention of VTE in patients undergoing orthopedic surgery. Results of ADVANCE-2 were first presented in July 2009 at the 22nd Congress of the International Society on Thrombosis and Haemostasis in Boston. The ADVANCE-3 data will be submitted for publication and presentation in 2010.

Apixaban is a novel, oral, highly selective Factor Xa inhibitor, a new class of agents being studied for the potential to prevent and treat blood clots in the veins and arteries.

Source:

http://www.bms.com/

Posted in: Pharmaceutical News

Tags: , , , , , , ,

Comments (0)

Suggested Reading

What does the future hold for obesity medication development?
Simple pre-surgical protocol can help prevent dangerous post-surgical infections
Columbia researchers secure $38.95 million ARPA-H contract to build a living knee replacement
Breakthrough obesity treatments on the horizon, rivaling surgery's success
Google Gemini and Bard pass the ophthalmology board examination
Delirium linked to tripled dementia risk in older adults, Australian study finds
Study reveals key gut microbiome differences in prediabetic patients
Integrating machine learning and gait analysis into orthopedic practice can lead to more effective care

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
(Logout)
Post

Newsletters you may be interested in

See all Newsletters »

Terms

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

Provide Feedback

You might also like...
Researchers identify increased brain tumor risk with specific contraceptive use